Recent public disclosures highlight DSwiss's strategic collaboration with RECOMM Co Ltd for COVID-19 sterilizer products and the launch of a new DNA testing business, reflecting diversification and innovation efforts.

• DSwiss announced a strategic collaboration with Japan-listed RECOMM Co Ltd for a "COVID-19 Killer" air and surface sterilizer and purifier [N1].
• In 2020, DSwiss announced the launch of a new DNA testing business [N2].

DSwiss Inc benefits from a diversified product portfolio addressing growing consumer demand for health, beauty, and wellness products. Its turnkey OEM/ODM model offers clients customized, high-quality formulations with regulatory and marketing support, positioning it as a preferred partner in the nutraceutical and personal care sectors. The company's strategic collaborations, such as with RECOMM Co Ltd for COVID-19 sterilizer products, and expansion into DNA testing and pet wellness segments, demonstrate adaptability and innovation. Ongoing investments in talent acquisition, R&D, and global marketing initiatives support its growth ambitions and potential to capture new markets [S1][N1][N2].

DSwiss Inc faces challenges including operating at a net loss as reported in fiscal 2025, with limited liquidity indicated by a current ratio below 1. The company operates in highly competitive and rapidly evolving health and beauty markets, requiring continuous innovation and marketing investment. Its smaller reporting company status limits disclosure of certain risk factors, potentially obscuring some operational risks. Expansion into new markets and product lines carries execution risks, and reliance on OEM/ODM clients may expose it to customer concentration and pricing pressures. Regulatory compliance across multiple jurisdictions also presents ongoing challenges [S1].

DSwiss Inc's moat is built on its comprehensive turnkey OEM/ODM manufacturing capabilities, combining advanced R&D, strict quality control, and regulatory compliance across multiple jurisdictions. Its broad product portfolio spanning nutraceuticals, skincare, personal care, and pet wellness, coupled with a strong distributor network and strategic partnerships, supports market penetration in Asia-Pacific and beyond. The company's commitment to innovation, evidenced by its in-house R&D and adherence to high industry standards, creates barriers to entry for competitors. Additionally, its regulatory expertise and ability to provide end-to-end solutions including marketing and packaging consultancy enhance client retention and brand trust [S1].

• Financial Performance and Liquidity: The company reported a net loss of $76,860 for fiscal 2025 and has a current ratio of 0.71, indicating potential liquidity constraints that could impact operations and growth.
• Market Competition and Innovation: Operating in dynamic health and beauty sectors requires continuous innovation and marketing to maintain competitiveness, which may strain resources.
• Regulatory Compliance: DSwiss must comply with multiple regulatory standards across jurisdictions, which involves complexity and risk of non-compliance affecting product approvals and market access.
• Execution Risks in Expansion: Efforts to expand globally and diversify product offerings involve execution risks including market acceptance, operational scaling, and integration of acquisitions.

• DSwiss Inc is a Nevada corporation incorporated on May 28, 2015, operating through wholly-owned subsidiaries including DSwiss Holding Limited (Seychelles), DSwiss (HK) Limited (Hong Kong), and DSwiss Sdn Bhd (Malaysia) [S1].
• The company is primarily engaged in supplying high-quality health and beauty products including weight management beverages, anti-aging solutions, and immune system enhancers [S1].
• DSwiss is a biotech nutraceutical firm and turnkey Private Label ODM/OEM provider specializing in healthcare, skincare, and personal care solutions, using natural ingredients and maintaining quality from raw material sourcing to packaging [S1].
• The product portfolio includes functional foods, health supplements, skincare, personal care, pet wellness products, traditional medicines, meal replacements, and complete nutrition products [S1].
• The company operates in multiple countries across Asia-Pacific including Malaysia, Singapore, Indonesia, Hong Kong, Australia, Taiwan, Macau, and China, with plans to expand globally [S1].
• DSwiss emphasizes innovation and quality, with a dedicated R&D team developing evidence-based, high-value formulations and adhering to regulatory standards such as GMP, HACCP, JAKIM Halal, ISO, and MESTI [S1].
• The company offers comprehensive OEM and ODM services including product development, manufacturing, packaging, regulatory licensing, and marketing support [S1].
• DSwiss has a strong distributor network and is expanding its market presence through social media campaigns, e-commerce platforms, and participation in international trade shows [S1].
• The company has 30 full-time employees as of December 31, 2025, including CEO Vincent Leong, and plans to expand its workforce by 50% by the end of 2026 [S1].
• DSwiss reported revenue of $2,920,986 for the year ended December 31, 2025, mainly from OEM/ODM sales of nutraceutical, skincare, and medical consumable supplies [S1].
• The company reported a net loss of $76,860 for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.0004 per share [S1].
• As of December 31, 2025, DSwiss had cash and cash equivalents of $285,034, current assets of $331,773, and current liabilities of $465,464, resulting in a current ratio of 0.71 and a cash ratio of 0.61 [S1].
• DSwiss announced a strategic collaboration with Japan-listed RECOMM Co Ltd for a "COVID-19 Killer" air and surface sterilizer and purifier [N1].
• In 2020, DSwiss announced a new DNA testing business [N2].
• The company is actively pursuing strategic mergers and acquisitions in healthcare, biotechnology, beauty, slimming, wellness, and food science sectors to drive growth and unlock synergies [S1].
• DSwiss maintains strict quality control and assurance processes, sourcing premium natural active ingredients and complying with Malaysian Ministry of Health regulations [S1].
• The company provides regulatory services to ensure smooth market entry, preparing documentation for authorities including the Ministry of Health Malaysia and HALAL certification bodies [S1].
• DSwiss offers customized pet care products and wellness supplements designed to support pet health, skin, joint mobility, and immune function [S1].
• The company is expanding its marketing efforts with targeted social media campaigns, influencer collaborations, and plans to participate in major international trade shows such as Vitafoods Asia [S1].
• DSwiss has trademark registrations in multiple jurisdictions including Cambodia, Malaysia, Singapore, China, Hong Kong, India, Myanmar, Vietnam, and the EUIPO [S1].
• There are no pending legal proceedings or claims believed to have a material adverse effect on the company [S1].
• DSwiss is a smaller reporting company and is not required to provide certain risk factor disclosures under SEC rules [S1][S2].